Infigratinib is a selective FGFR1-3 inhibitor in development for the treatment of cholangiocarcinoma and other FGFR-driven diseases such as achondroplasia. (Source)

An observational research study designed to learn more about the overall health, growth, and possible medical complications in children with achondroplasia (a bone growth disorder). No medication will be administered; however, children successfully enrolled in PROPEL for 6 months or more may be eligible for subsequent treatment trials sponsored by QED Therapeutics, including PROPEL 2.

Learn more about PROPEL and PROPEL 2 Studies of Infigratinib for achondroplasia.